Strodium ranelate

Strodium ranelate is an antiosteoporotic agent that increases bone formation and reduces bone resorption, thus resulting in a rebalance of bone tiunover, in favour of bone formation. Strodixun ranelate stimulates the calcium sensing receptors and leads to the differentiation of pre-osteoblasts to osteoblasts, which increases the bone formation. 

Strodium ranelate is restricted to second-line treatment of severe osteoporosis in postmenopausal women at high risk of fracture, and in men at increased risk of fracture. A review of available safety data for strodixun ranelate has raised concern about its cardiovascular safety beyond the already recognised risk of venous thromboembolism. An analysis of randomised controlled trial data has identified an increased risk of serious cardiac disorders, including myocardial infarction [65 ]. 

In order to minimise the risks, it is advised that strodium ranelate should not be used in patients with ischaemic heart disease, peripheral arterial disease, cerebrovascular disease or in patients with xmcontroUed hypertension. Finally, prescribers are advised of the patient s risk of developing cardiovascular disease before starting treatment and thereafter at regular intervals. 

Anonymous. Strodium ranelate. Risk of serious cardiac disorders-restricted indications, new contra-indications, and warnings. WHO News-... 

Anonymous. Strodium ranelate. Recommendations to restrict the use and further review started. WHO Newslett 2013 4 7. 

---